Roche annual report

 Roche gross annual report Dissertation

1

Roche

2013 results

London, 31 January 2014

2

This presentation is made up of certain forward-looking statements. These kinds of forward-looking claims may be determined by phrases such as ‘believes', ‘expects', ‘anticipates', ‘projects', ‘intends', ‘should', ‘seeks', ‘estimates', ‘future' or identical expressions or by exploration of, among other things, strategy, goals, programs or motives. Various elements may cause real results to vary materially down the road from individuals reflected in forward-looking transactions contained in this presentation, among others:

1

a couple of

3

5

5

six

7

8

9

twelve

11

pricing and merchandise initiatives of competitors;

legislative and regulatory developments and economic circumstances; delay or perhaps inability in obtaining regulating approvals or perhaps bringing goods to market; variances in currency exchange rates and general financial market circumstances; uncertainties inside the discovery, expansion or promoting of new goods or fresh uses of existing items, including with no limitation adverse results of clinical trials or perhaps research projects, unpredicted side-effects of pipeline or marketed items;

increased federal government pricing stresses;

interruptions in production;

lack of or failure to obtain enough protection for intellectual home rights; a lawsuit;

loss of important executives or other personnel; and

unfavorable publicity and news coverage.

Any claims regarding profits per discuss growth is definitely not a profit forecast and really should not always be interpreted to mean that Roche's earnings or perhaps earnings per share just for this year or any type of subsequent period will always match or perhaps exceed the historical published earnings or perhaps earnings every share of Roche. Intended for marketed products discussed with this presentation, you should see full prescribing information about our web page www.roche.com

Most mentioned art logos are legitimately protected.

several

Group

Severin Schwan

Ceo

4

2013 performance

View

5

2013: Targets totally achieved

Objectives for 2013

FY 2013

Group product sales

In line with revenue growth noted in 20121

+6%

пѓј

Core EPS

Ahead of revenue growth1

+10%

пѓј

Dividend

Further boost dividend

CHF 7. 70

+6%

пѓј

1At

continuous exchange prices

Excluding one-off Past Service Income effects of CHF 236m in core net income and eliminating 340B hold release effect of CHF 182m on sales and CHF 94m on primary net income

2013 dividend since proposed by the Board of Directors

6th

2013 Shows

Innovation

• HER2 business secured through Kadcyla, Perjeta and Herceptin SC • Haematology operation strengthened through Gazyva in CLL • 15 compounds in late-stage development, strong emerging portfolio in immunology/ophthalmology

• Cobas 8100 lastest automation system launched

Progress

• 3 major new medicine commences: Perjeta in EU, Kadcyla in US and EU, Gazyva in US

• Strong development for oncology franchise, Actemra and Lucentis

• Even more financial deleverage contributing to EPS momentum

six

2013: Strong sales growth

2013

CHFbn

2012

CHFbn

Change in %

CHF

CER

Pharmaceuticals Division

36. a few

35. two

3

7

Diagnostics Division

10. 5

10. three or more

2

5

Roche Group

46. almost eight

45. a few

3

6th

8

CER=Constant Exchange Rates

Group: Solid sales development sustained

2013: +6%

10%

8%

8%

6%

6%

4%

4%

2%

6%

4%

2%

0%

4%

6%

Eliminating

340B revenue

reserves relieve

1%

0%

-2%

6%

7%

0%

-3%

-4%

-5%

-6%

Q3

10

Q4

twelve

Q1

10

Q2

11

Q3

11

Q4

14

Q1

12

Q2

12

Q3

12

Q4

doze

Q1

13

Q2

13

Q3

13

Q4

13

9

All values by constant exchange rates

Group operating income and perimeter

33. 2%

34. 9%

35. 6%

37. 7%

38. 3%

% of sales

+8%1

16. 3

16. 6

2009

2010

17. a couple of

17. being unfaithful

15. 1

CHFbn

you

At frequent exchange rates

2011

2012

2013

12

Strong working free income

35. five per cent

31. 9%

30. 0%...

Popular